<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0"><channel><title>ClinicalConnection.com New Clinical Trials</title><link>http://www.clinicalconnection.com/NewsWire.aspx</link><description>The latest clinical studies from ClinicalConnection.com - Tomorrow's cures are in clinical trials today!</description><copyright>(c) 1998-2012, ClinicalConnection, Inc. All rights reserved.</copyright><ttl>5</ttl><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/NewClinicalTrials" /><feedburner:info uri="newclinicaltrials" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item><title>Chronic Pain - Bradenton FL</title><description>&lt;a href="/StudyFlyer/Study14717Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study14717Flyer.jpg" alt="Study 14717 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/rwoW6gT0V1A" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/rwoW6gT0V1A/patientviewstudy14717.aspx</link><pubDate>5/24/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14717.aspx</feedburner:origLink></item><item><title>High Cholesterol - Pompano Beach FL</title><description>High Cholesterol and Climbing?  Male and Females 18 years of older are needed to volunteer in a clinical research study.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/lYb7w9YpT4k" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/lYb7w9YpT4k/patientviewstudy14718.aspx</link><pubDate>5/24/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14718.aspx</feedburner:origLink></item><item><title>Celiac Disease - Boone NC</title><description>&lt;a href="/StudyFlyer/Study14250Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study14250Flyer.jpg" alt="Study 14250 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;!-- Start of StatCounter Code for Default Guide --&gt;
&lt;script type="text/javascript"&gt;
var sc_project=7888207; 
var sc_invisible=1; 
var sc_security="e9a79f3e"; 
&lt;/script&gt;
&lt;script type="text/javascript"
src="http://www.statcounter.com/counter/counter.js"&gt;&lt;/script&gt;
&lt;noscript&gt;&lt;div class="statcounter"&gt;&lt;a title="joomla site
stats" href="http://statcounter.com/joomla/"
target="_blank"&gt;&lt;img class="statcounter"
src="http://c.statcounter.com/7888207/0/e9a79f3e/1/"
alt="joomla site stats"&gt;&lt;/a&gt;&lt;/div&gt;&lt;/noscript&gt;
&lt;!-- End of StatCounter Code for Default Guide --&gt;

&lt;script type="text/javascript"&gt;

  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-227598-129']);
  _gaq.push(['_trackPageview']);

  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();

&lt;/script&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/fCfnA9o9Wbg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/fCfnA9o9Wbg/patientviewstudy14716.aspx</link><pubDate>5/23/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14716.aspx</feedburner:origLink></item><item><title>Acne Vulgaris - Bronx NY</title><description>Do you struggle with Acne?&lt;br /&gt;&lt;br /&gt;

Have pimples taken control of your face? Has Acne made you lose control of your own skin?  &lt;br /&gt;
If so, then you may qualify for a clinical research study of an investigational topical gel for facial acne.  &lt;br /&gt;&lt;br /&gt;

Qualified participants ages 12-40 will receive study-related medical care and study medication at no cost and may be compensated up to $100 for time and travel. &lt;br /&gt;&lt;br /&gt;

There is no cost to you and health insurance is not needed! &lt;br /&gt;&lt;br /&gt;

Call Fordham Dermatology now for more information and to see if you or your child may qualify.&lt;br /&gt;&lt;br /&gt;

Stop hiding from facial acne and call now.   &lt;br /&gt;&lt;br /&gt;

Open evenings and weekends&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Fa5OWOGpaXE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Fa5OWOGpaXE/patientviewstudy14714.aspx</link><pubDate>5/23/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14714.aspx</feedburner:origLink></item><item><title>Facial Acne - Katy TX</title><description>Facial Acne Research Study – This acne research study is for those 12 to 40 years of age (those 17 and younger must have a parent/legal guardian to sign consent) who have moderate to severe facial acne.  The purpose of this study is to evaluate 2 different study gels versus placebo. Participants have 4 visits over 12 weeks and are compensated up to $300.00 for time and travel.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/wW5eKN4jOWA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/wW5eKN4jOWA/patientviewstudy14715.aspx</link><pubDate>5/23/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14715.aspx</feedburner:origLink></item><item><title>Anti-Depressant Induced Sexual Dysfunction - Cincinnati OH</title><description>&lt;a href="/StudyFlyer/Study12806Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study12806Flyer.jpg" alt="Study 12806 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/fOxhMqjKVZ4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/fOxhMqjKVZ4/patientviewstudy14705.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14705.aspx</feedburner:origLink></item><item><title>Anti-Depressant Induced Sexual Dysfunction - St. Louis MO</title><description>&lt;a href="/StudyFlyer/Study12806Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study12806Flyer.jpg" alt="Study 12806 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/iA9Eva2XqIs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/iA9Eva2XqIs/patientviewstudy14706.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14706.aspx</feedburner:origLink></item><item><title>Anti-Depressant Induced Sexual Dysfunction - Lake Charles LA</title><description>&lt;a href="/StudyFlyer/Study12806Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study12806Flyer.jpg" alt="Study 12806 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/ksrp1rvwcs8" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/ksrp1rvwcs8/patientviewstudy14707.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14707.aspx</feedburner:origLink></item><item><title>Anti-Depressant Induced Sexual Dysfunction - San Antonio TX</title><description>&lt;a href="/StudyFlyer/Study12806Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study12806Flyer.jpg" alt="Study 12806 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/eWz2s8eKE-E" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/eWz2s8eKE-E/patientviewstudy14708.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14708.aspx</feedburner:origLink></item><item><title>Anti-Depressant Induced Sexual Dysfunction - San Diego CA</title><description>&lt;a href="/StudyFlyer/Study12806Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study12806Flyer.jpg" alt="Study 12806 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/NSaER-GrM4Y" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/NSaER-GrM4Y/patientviewstudy14709.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14709.aspx</feedburner:origLink></item><item><title>Painful Menstruation - Chicago IL</title><description>This research is being conducted on an experimental drug called KYG0395. The purpose of the study is to evaluate the safety and efficacy of KYG0395 in female subjects 18 to 35 years of age with primary dysmenorrhea (menstrual cramps). The study will also evaluate if taking KYG0395 is better than taking a placebo.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/wUWpZaYqpi0" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/wUWpZaYqpi0/patientviewstudy14710.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14710.aspx</feedburner:origLink></item><item><title>Obstructive Sleep Apnea - Chicago IL</title><description>If you decide to take part in this study you will receive either liraglutide or an inactive drug
(placebo). Placebo is identical in appearance to the active drug but contains no active ingredient.
For this study the term “study drug” refers to both liraglutide and placebo.
This study will assess the effect of a liraglutide-induced weight loss on obstructive sleep apnea.
This study is part of an international program and is planned to take place in Canada and the U.S.
It will include approximately 308 men and women 18 – 64 years of age.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/lBIRX0zdJvE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/lBIRX0zdJvE/patientviewstudy14711.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14711.aspx</feedburner:origLink></item><item><title>Irritable Bowel Syndrome with Diarrhea - Hurst TX</title><description>&lt;a href="/StudyFlyer/Study14712Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study14712Flyer.jpg" alt="Study 14712 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/lO6RLGXebGQ" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/lO6RLGXebGQ/patientviewstudy14712.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14712.aspx</feedburner:origLink></item><item><title>Anemia and Uterine Fibroids - Raleigh NC</title><description>Are you tired of your anemia due to uterine fibroids? The heavy bleeding has not only made your period worse it has also caused your anemia. Your body is going through a lot already, and now your anemia is making you tired, pale and weak. 

Wake Research Associates is now conducting a research study to measure the safety and effectiveness (how well it works) of an investigational medication for anemia due to uterine fibroids.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/_MILCA2SreI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/_MILCA2SreI/patientviewstudy14713.aspx</link><pubDate>5/22/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14713.aspx</feedburner:origLink></item><item><title>Chronic Pain - Houston TX</title><description>An open-label, multicenter study to assess the long-term safety of once-daily study medication in subjects with moderate to severe chronic nonmalignant and nonneuropathic pain.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/LZCNh-7tf_U" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/LZCNh-7tf_U/patientviewstudy14701.aspx</link><pubDate>5/21/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14701.aspx</feedburner:origLink></item><item><title>Chronic Low Back Pain - Houston TX</title><description>A multi-center, randomized, double-blind, placebo-controlled study with an open-label run-in to assess the efficacy and safety of once-daily study medication in subjects with moderate to severe chronic low back pain.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/9Foddov3Bn4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/9Foddov3Bn4/patientviewstudy14702.aspx</link><pubDate>5/21/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14702.aspx</feedburner:origLink></item><item><title>Type II Diabetes - Hurst TX</title><description>&lt;a href="/StudyFlyer/Study14704Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study14704Flyer.jpg" alt="Study 14704 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/_BIB8b7KLYg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/_BIB8b7KLYg/patientviewstudy14704.aspx</link><pubDate>5/21/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14704.aspx</feedburner:origLink></item><item><title>Healthy Volunteers (Ages 18-55) - Baltimore MD</title><description>&lt;a href="/StudyFlyer/Study14697Flyer.jpg" rel="facebox"&gt;&lt;img width="500" src="/StudyFlyer/Study14697Flyer.jpg" alt="Study 14697 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/X7B60YERmrc" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/X7B60YERmrc/patientviewstudy14697.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14697.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - New Britain CT</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/3XMI-A8AYLU" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/3XMI-A8AYLU/patientviewstudy14686.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14686.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Danbury CT</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/w9p15Clqj84" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/w9p15Clqj84/patientviewstudy14687.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14687.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Norwalk</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/phHD1Pth8GE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/phHD1Pth8GE/patientviewstudy14688.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14688.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - East Norwalk</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/SseIxeTo4Vc" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/SseIxeTo4Vc/patientviewstudy14689.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14689.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Orlando FL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/rWb4D6rnnpg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/rWb4D6rnnpg/patientviewstudy14690.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14690.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Hialeah FL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/NLwpHMGXUrY" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/NLwpHMGXUrY/patientviewstudy14691.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14691.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Fort Lauderdale FL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/JFh7EaN3D-E" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/JFh7EaN3D-E/patientviewstudy14692.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14692.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Port Saint Lucie FL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/qepNYykV5Xk" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/qepNYykV5Xk/patientviewstudy14693.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14693.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Waukegan IL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/c7xWJLzIuH0" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/c7xWJLzIuH0/patientviewstudy14694.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14694.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Elgin IL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/zMueaafDa6c" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/zMueaafDa6c/patientviewstudy14695.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14695.aspx</feedburner:origLink></item><item><title>Osteoarthritis of the Knee - Joliet IL</title><description>&lt;a href="/StudyFlyer/Study12517Flyer.jpg" rel="facebox"&gt;&lt;img width="300" src="/StudyFlyer/Study12517Flyer.jpg" alt="Study 12517 Flyer" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;em&gt;Click image to enlarge&lt;/em&gt;&lt;br /&gt;&lt;br /&gt;
Mytrus, Inc, is studying an investigational electromagnetic
device that has been successfully used for pain relief.
This clinical trial will evaluate if this technology is effective
in reducing the pain of knee osteoarthritis.&lt;br /&gt;&lt;br /&gt;

This study is conducted in the privacy of your own home.&lt;br /&gt;&lt;br /&gt;
This device is:&lt;ul /&gt;
&lt;li&gt; non-invasive&lt;/li&gt; 
&lt;li&gt; easy to use&lt;/li&gt;
&lt;li&gt; has no known risks or side effects&lt;/li&gt;
&lt;li&gt; requires just two 15 minute treatments per day&lt;/li&gt;&lt;/ul&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Tg5AiEEw9O4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Tg5AiEEw9O4/patientviewstudy14696.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14696.aspx</feedburner:origLink></item><item><title>Major Depression Disorder - Houston TX</title><description>A randomized, double-blind, placebo-controlled, relapse prevention study with vilazodone in patients with major depressive disorder.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/BFv8QXWoR_k" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/BFv8QXWoR_k/patientviewstudy14682.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14682.aspx</feedburner:origLink></item><item><title>Hepatitis C - Houston TX</title><description>A phase 3, safety and efficacy study of boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC subjects.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/WK1zGQ7H-XM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/WK1zGQ7H-XM/patientviewstudy14683.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14683.aspx</feedburner:origLink></item><item><title>Depression - Glendale CA</title><description>Investigational drug for depression.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/5SNmPpc-pfI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/5SNmPpc-pfI/patientviewstudy14684.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14684.aspx</feedburner:origLink></item><item><title>Mild Memory Loss - Glendale CA</title><description>Series of tests to determine the health of your brain. Tests may include an initial memory test (Cog-State), lab tests, state-of-the-art fMRI and PET scan.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/gRUXXvqLEv8" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/gRUXXvqLEv8/patientviewstudy14685.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14685.aspx</feedburner:origLink></item><item><title>Depression - Upland CA</title><description>Depressed?&lt;br /&gt;&lt;br /&gt;

Do you struggle with feelings of sadness, worthlessness or guilt?&lt;br /&gt;
Do you lack motivation or find it difficult to concentrate?&lt;br /&gt;&lt;br /&gt;

Are there nights you can’t fall asleep?  Or is it difficult to get out of bed in the morning?&lt;br /&gt;&lt;br /&gt;

If so, you may be suffering from Major Depressive Disorder and you may qualify for a research study, evaluating an investigational medication for depression.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/XVL6hapkXJs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/XVL6hapkXJs/patientviewstudy14698.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14698.aspx</feedburner:origLink></item><item><title>Depression - Orange CA</title><description>Depressed?&lt;br /&gt;&lt;br /&gt;

Do you struggle with feelings of sadness, worthlessness or guilt?&lt;br /&gt;
Do you lack motivation or find it difficult to concentrate?&lt;br /&gt;&lt;br /&gt;

Are there nights you can’t fall asleep?  Or is it difficult to get out of bed in the morning?&lt;br /&gt;&lt;br /&gt;

If so, you may be suffering from Major Depressive Disorder and you may qualify for a research study, evaluating an investigational medication for depression.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Ep86OtR_sqk" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Ep86OtR_sqk/patientviewstudy14699.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14699.aspx</feedburner:origLink></item><item><title>Treatment Resistant Depression - Arcadia CA</title><description>Not seeing the results you want from your antidepressant?&lt;br /&gt;&lt;br /&gt;

Our office is conducting a research study to evaluate whether adding an investigational medication to an approved antidepressant therapy might give relief from the symptoms of major depressive disorder (MDD) when added to a current medication.&lt;br /&gt;&lt;br /&gt;

The study lasts 15 - 22 weeks.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Y8_xHqQ5shI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Y8_xHqQ5shI/patientviewstudy14700.aspx</link><pubDate>5/18/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14700.aspx</feedburner:origLink></item><item><title>Crohn's Disease - Tuscon AZ</title><description>&lt;b&gt;Treating your Crohn’s disease doesn’t have to be a solo act. &lt;br /&gt;&lt;br /&gt;

About the studies&lt;/b&gt;&lt;br /&gt;
We know that having active Crohn’s disease can be painful and frustrating, especially if you’ve been unresponsive to anti-TNF (tumor necrosis factor) medications. OPERA and ANDANTE are two clinical research studies that are bringing together hundreds of people like you to evaluate medications in development (study drugs) that are intended to reduce the symptoms of Crohn’s disease, particularly those related to inflammation of the gastrointestinal tract. &lt;br /&gt;&lt;br /&gt;

The OPERA and ANDANTE studies are two Phase 2 clinical research studies for adults with active Crohn’s disease. The main purpose of each of these studies is to evaluate the safety and effectiveness of a study drug. Several hundred adults in the United States and other countries are expected to participate in these studies. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the study drug&lt;/b&gt;&lt;br /&gt;
The OPERA study drug (PF-00547659) and the ANDANTE study drug (PF-04236921) are both man-made antibodies. Although both study drugs are intended to reduce the symptoms of Crohn’s disease, particularly those related to inflammation of the gastrointestinal tract, they do so by targeting different mechanisms of the disease process.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate? &lt;/b&gt;&lt;br /&gt;
You may be eligible to participate in the OPERA or ANDANTE clinical research study if you:&lt;ul&gt;&lt;br /&gt;

&lt;li&gt; Are between 18 and 75 years old&lt;/li&gt;
&lt;li&gt; Have active Crohn’s disease&lt;/li&gt;
&lt;li&gt; Have stopped responding or failed to respond to a class of drugs called anti-TNF medications (e.g., infliximab [Remicade®], adalimumab [Humira®], certolizumab pegol [Cimzia®])&lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor can review with you if you are interested in participating in one of these clinical research studies. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What does the study involve? &lt;/b&gt;&lt;br /&gt;
If you choose to participate, you will be asked to: &lt;ul&gt;&lt;br /&gt;

&lt;li&gt; Sign an informed consent document before beginning any study-related activities&lt;/li&gt;
&lt;li&gt; Attend up to 20 study visits for up to 28 months &lt;/li&gt;
&lt;li&gt; Complete questions daily for 3 months about your well-being on a handheld device&lt;/li&gt;
&lt;li&gt; Keep a daily paper diary to record the use of any steroids and medicines you take for diarrhea &lt;/li&gt;
&lt;li&gt; Provide stool samples &lt;/li&gt;
&lt;li&gt; Have a colonoscopy and other study-related exams and procedures&lt;/li&gt;
&lt;li&gt; Participants will receive 1 of 3 different doses of a study drug or a placebo, which looks like the study drug but does not contain any active medication. There is a 75 percent (3 in 4) chance that participants will receive a study drug and a 25 percent (1 in 4) chance of receiving a placebo&lt;/li&gt;&lt;/ul&gt;

You may or may not benefit from participating in these studies. Your participation will allow the study sponsor to investigate alternative treatment options that may benefit others with Crohn’s disease in the future. 

&lt;a title="godaddy statistics"
href="http://statcounter.com/godaddy_website_tonight/"
target="_blank"&gt;&lt;img
src="http://c.statcounter.com/7054072/0/463925bd/1/"
alt="godaddy statistics" border="0"&gt;&lt;/a&gt;

&lt;script type="text/javascript"&gt;

  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-227598-116']);
  _gaq.push(['_trackPageview']);

  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();

&lt;/script&gt;&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/NOq8jetqkuo" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/NOq8jetqkuo/patientviewstudy14681.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14681.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Haverhill MA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/oBMVRI3-eLQ" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/oBMVRI3-eLQ/patientviewstudy14607.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14607.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Springfield MA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/eszHZQc3Wvs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/eszHZQc3Wvs/patientviewstudy14608.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14608.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Boston MA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/cwkAEblDeeA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/cwkAEblDeeA/patientviewstudy14609.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14609.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Newton Center MA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/SB2qeVTE9wk" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/SB2qeVTE9wk/patientviewstudy14610.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14610.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - East Providence RI</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/lLHkJ1I2zYg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/lLHkJ1I2zYg/patientviewstudy14611.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14611.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Bennington VT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/7wj4jWBkvLE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/7wj4jWBkvLE/patientviewstudy14612.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14612.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - New Haven CT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/pr-dsW-kfaI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/pr-dsW-kfaI/patientviewstudy14613.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14613.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Waterbury CT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/J1l5S_r_Ixw" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/J1l5S_r_Ixw/patientviewstudy14614.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14614.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Danbury CT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/_lSK2Sj5cRw" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/_lSK2Sj5cRw/patientviewstudy14615.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14615.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Fairfield CT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/59RGiY3qeyo" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/59RGiY3qeyo/patientviewstudy14616.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14616.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Berlin NJ</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/AU3hCkvUY1w" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/AU3hCkvUY1w/patientviewstudy14617.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14617.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Toms River NJ</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/axybnBUOgmk" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/axybnBUOgmk/patientviewstudy14618.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14618.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Manchester Township NJ</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/TZICn9m6JzE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/TZICn9m6JzE/patientviewstudy14619.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14619.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Liverpool NY</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/A97XD50lZIA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/A97XD50lZIA/patientviewstudy14620.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14620.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Pittsburgh PA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/LM7ETYMe3YA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/LM7ETYMe3YA/patientviewstudy14621.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14621.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Jenkintown PA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/5Z_Fj_-7f9Q" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/5Z_Fj_-7f9Q/patientviewstudy14622.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14622.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Rockville MD</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/SzS0qXFePQI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/SzS0qXFePQI/patientviewstudy14623.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14623.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Alexandria VA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/xOF7a1aTNuk" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/xOF7a1aTNuk/patientviewstudy14624.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14624.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Raleigh NC</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/pZSFu1VY2JY" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/pZSFu1VY2JY/patientviewstudy14625.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14625.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Hickory NC</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/MqE1b8ljyvE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/MqE1b8ljyvE/patientviewstudy14626.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14626.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Asheville NC</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/ksQEFtIMJNM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/ksQEFtIMJNM/patientviewstudy14627.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14627.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Greer SC</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/kSIRZ0IAVnQ" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/kSIRZ0IAVnQ/patientviewstudy14628.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14628.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Decatur GA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/6HfPb-DvNjc" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/6HfPb-DvNjc/patientviewstudy14629.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14629.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Lawrenceville GA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Vyu3YWPxk-A" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Vyu3YWPxk-A/patientviewstudy14630.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14630.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Atlanta GA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/-x7AkTl52yM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/-x7AkTl52yM/patientviewstudy14631.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14631.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Columbus GA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/2vPziO3jCaw" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/2vPziO3jCaw/patientviewstudy14632.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14632.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Fort Walton Beach FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/CbLgTXjWVEg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/CbLgTXjWVEg/patientviewstudy14633.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14633.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Hallandale FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/UlCgDkLPWhU" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/UlCgDkLPWhU/patientviewstudy14634.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14634.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Miami FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/FXzqo-Vc4dQ" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/FXzqo-Vc4dQ/patientviewstudy14635.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14635.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - West Palm Beach FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Lulb32k9ca4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Lulb32k9ca4/patientviewstudy14636.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14636.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Palm Beach Gardens FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/TmrxgI3spBs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/TmrxgI3spBs/patientviewstudy14637.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14637.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Delray Beach FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/-IuZnh4RHGY" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/-IuZnh4RHGY/patientviewstudy14638.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14638.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Lake Worth FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/QXOHmur_Az8" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/QXOHmur_Az8/patientviewstudy14639.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14639.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Tampa FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/6TzvOaA8ehg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/6TzvOaA8ehg/patientviewstudy14640.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14640.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Fort Myers FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Eh7nBvbnSpA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Eh7nBvbnSpA/patientviewstudy14641.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14641.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Port Charlotte FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/XYFHDs8nGe0" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/XYFHDs8nGe0/patientviewstudy14642.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14642.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Bradenton FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/5ZShQZUVwyw" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/5ZShQZUVwyw/patientviewstudy14643.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14643.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Sarasota FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/j-qz0KJwRjs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/j-qz0KJwRjs/patientviewstudy14644.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14644.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Ocala FL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/AITrehiVsGo" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/AITrehiVsGo/patientviewstudy14645.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14645.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Birmingham AL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/CFzcdfTZ1tU" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/CFzcdfTZ1tU/patientviewstudy14646.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14646.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Cordova TN</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/euMwCuCEoSs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/euMwCuCEoSs/patientviewstudy14647.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14647.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Hattiesburg MS</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/9DRfrUky6OA" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/9DRfrUky6OA/patientviewstudy14648.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14648.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Paducah KY</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/n1TEsaiRuV4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/n1TEsaiRuV4/patientviewstudy14649.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14649.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Toledo OH</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/JC_L0k7UuNs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/JC_L0k7UuNs/patientviewstudy14650.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14650.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Elkhart IN</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/Y4a3JH-fxHM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/Y4a3JH-fxHM/patientviewstudy14651.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14651.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Evansville IN</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/YltNoliS3jE" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/YltNoliS3jE/patientviewstudy14652.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14652.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Great Falls MT</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/QP1_59FctDs" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/QP1_59FctDs/patientviewstudy14653.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14653.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Elk Grove Village IL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/a0aOFjp70MU" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/a0aOFjp70MU/patientviewstudy14654.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14654.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Peoria IL</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/d8N-mINGR2o" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/d8N-mINGR2o/patientviewstudy14655.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14655.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Kansas City MO</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/lSxi0VvnTR0" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/lSxi0VvnTR0/patientviewstudy14656.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14656.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Wichita KS</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/770Kxdxedlo" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/770Kxdxedlo/patientviewstudy14657.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14657.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - New Orleans LA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/9rX40ZpK0og" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/9rX40ZpK0og/patientviewstudy14658.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14658.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Lake Charles LA</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/zCt8c7KjGRg" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/zCt8c7KjGRg/patientviewstudy14659.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14659.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Little Rock AR</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/1HQMx2yxZuY" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/1HQMx2yxZuY/patientviewstudy14660.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14660.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Oklahoma City OK</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/ZltENFj5ubo" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/ZltENFj5ubo/patientviewstudy14661.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14661.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Dallas TX</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/M-cVGJXJCyw" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/M-cVGJXJCyw/patientviewstudy14662.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14662.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Wichita Falls TX</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/EOqbtoFNIrI" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/EOqbtoFNIrI/patientviewstudy14663.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14663.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - San Antonio TX</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/YtGdADqF9Ew" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/YtGdADqF9Ew/patientviewstudy14664.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14664.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - San Antonio TX</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/f3NYiZG2U38" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/f3NYiZG2U38/patientviewstudy14665.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14665.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Austin TX</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/ciyu0lbxwnY" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/ciyu0lbxwnY/patientviewstudy14666.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14666.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Denver CO</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/LTTOODhZMyM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/LTTOODhZMyM/patientviewstudy14667.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14667.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Boulder CO</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/zEne2xg3qu4" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/zEne2xg3qu4/patientviewstudy14668.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14668.aspx</feedburner:origLink></item><item><title>Alzheimer's Disease - Phoenix AZ</title><description>&lt;b&gt;Making memories is easy. Making them last is the hard part.&lt;/b&gt;&lt;br /&gt;
Current medications for Alzheimer’s disease focus on treating the symptoms, but they do not work to stop the disease from developing or from getting worse over time.  The 3133K1-3000 Alzheimer’s study is testing an investigational medication designed to slow the progression of the disease.&lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study&lt;/b&gt;&lt;br /&gt;
The main purpose of the 3133K1-3000 study is to evaluate an investigational medication called bapineuzumab to see if it may safely and effectively slow the progression of Alzheimer’s disease. To do this, researchers will evaluate and monitor study participants’ memory and other measures of brain function, as well as their ability to perform day-to-day activities. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;About the Study Drug&lt;/b&gt;&lt;br /&gt;
Recent advances in Alzheimer’s research suggest that a protein called beta-amyloid builds up in the brain and forms plaque. These plaques damage and destroy nerve cells and are thought to be related to the development of Alzheimer’s disease. Bapineuzumab is designed to target the beta-amyloid protein in the brain and help the body remove it. Removing the protein may slow down the buildup of plaque and in turn slow down the progression of Alzheimer’s disease. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Who can participate in the study? &lt;/b&gt;&lt;br /&gt;
You (or someone you know) may be eligible to participate if you:&lt;ul&gt;
&lt;li&gt; Are 50 to 88 years of age&lt;/li&gt;
&lt;li&gt; Have been diagnosed with mild to moderate Alzheimer’s disease &lt;/li&gt;
&lt;li&gt; Are able to have an MRI scan&lt;/li&gt;
&lt;li&gt; Have a caregiver who can come to all clinic visits &lt;/li&gt;&lt;/ul&gt;
There are other eligibility requirements that the study doctor or staff will review with you. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will the caregiver be asked to do? &lt;/b&gt;&lt;br /&gt;
The caregiver for this study will be asked to:&lt;ul&gt;
&lt;li&gt; Attend all study visits with the participant and stay until the visit is over&lt;/li&gt;
&lt;li&gt; Visit the participant approximately five times per week &lt;/li&gt;
&lt;li&gt; Answer questions and provide information about the participant’s activities, behavior, and how he or she is doing&lt;/li&gt;&lt;/ul&gt;
If for any reason the caregiver cannot continue to assist with the study, a new caregiver may take over the role. &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;What will happen during the study? &lt;/b&gt;&lt;br /&gt;
Participation will last for approximately 20 months. During this time, participants and caregivers will be required to visit the study clinic approximately 15 times. &lt;br /&gt;&lt;br /&gt;
Participants will have to:&lt;ul&gt;
&lt;li&gt; Come to the clinic with a caregiver&lt;/li&gt;
&lt;li&gt; Receive intravenous (IV) infusions &lt;/li&gt;
&lt;li&gt; Stay for up to 4 hours&lt;/li&gt;
&lt;li&gt; Answer questions &lt;/li&gt;
&lt;li&gt; Have exams and procedures  &lt;/li&gt;&lt;/ul&gt;

Throughout the study, participants will be monitored by a medical team, including a nurse or study coordinator and the study doctor. &lt;br /&gt;&lt;br /&gt;

Participants may or may not benefit from being in the study, but what we learn from the study may help improve treatment options for patients with Alzheimer’s disease in the future. Study participation is voluntary, and participants can leave the study at any time without it affecting the medical care they receive from their family doctor.  &lt;br /&gt;&lt;br /&gt;

&lt;b&gt;Where is the study taking place? &lt;/b&gt;&lt;br /&gt;
Sites may be added during the study, so please check back often if there are currently no sites located near you that you are willing to travel to at this time.&lt;img src="http://feeds.feedburner.com/~r/NewClinicalTrials/~4/TyStUeFMmhM" height="1" width="1"/&gt;</description><link>http://feedproxy.google.com/~r/NewClinicalTrials/~3/TyStUeFMmhM/patientviewstudy14669.aspx</link><pubDate>5/17/2012</pubDate><feedburner:origLink>http://www.clinicalconnection.com/patientviewstudy14669.aspx</feedburner:origLink></item></channel></rss>

